Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

Summary

this study aims to : 1. To compare the efficacy of combining low doses of Roxadustat Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase (PHD) inhibitor and iron versus standard treatment with erythropoietin-stimulating agents (ESA) in the treatment of anemia as a complication of chronic kidney disease (CKD) among dialysis-dependent patients. 2. To emphasize the safety profile of low doses of Roxadustat HIF-PHD. 3. To assess changes in the quality of life of patients with kidney disease before and after treatment.

Timeline

Start

2023-05-24

Primary completion

2024-08-30

Completion

2025-01-30

Drugs

Indications